Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTC21C in newly diagnosed multiple myeloma
NCT07297329Phase 3Recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Dec 2025
- Primary completion
- Dec 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of SCTC21C in multiple myeloma (MM), sponsored by Sinocelltech Group Limited. Started Dec 2025; status: recruiting.
02
Drugs
SCTC21C
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07297329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297329.